A novel MRI gadolinium-based contrast agent designed to bind with collagen, a key component in liver fibrosis progression, provides direct quantification of collagen deposition in several preclinical liver disease models. This tool could have large implications in clinical diagnosis and drug trials.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J. Hepatol. 69, 896–904 (2018).
Salarian, M. et al. Early detection and staging of chronic liver diseases with a protein MRI contrast agent. Nat Commun 10, 4777 (2019).
Tapper, E. B. & Lok, A. S. F. Use of liver imaging and biopsy in clinical practice. N. Engl. J. Med. 377, 756–768 (2017).
Zarski, J. P. et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J. Hepatol. 56, 55–62 (2012).
Kennedy, P. et al. Quantitative elastography methods in liver disease: current evidence and future directions. Radiology 286, 738–763 (2018).
Hernandez-Gea, V. & Friedman, S. L. Pathogenesis of liver fibrosis. Annu. Rev. Pathol. 6, 425–456 (2011).
Farrar, C. T. et al. CM-101: Type I collagen-targeted MR imaging probe for detection of liver fibrosis. Radiology 287, 581–589 (2018).
Xue, S. H. et al. Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging. Proc. Natl Acad. Sci. USA 112, 6607–6612 (2015).
Ellis, E. L. & Mann, D. A. Clinical evidence for the regression of liver fibrosis. J. Hepatol. 56, 1171–1180 (2012).
Sumida, Y. & Yoneda, M. Current and future pharmacological therapies for NAFLD/NASH. J. Gastroenterol. 53, 362–376 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Kennedy, P., Taouli, B. Collagen-targeted MRI contrast agent for liver fibrosis detection. Nat Rev Gastroenterol Hepatol 17, 201–202 (2020). https://doi.org/10.1038/s41575-020-0266-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-020-0266-z
